Posted inBiotechnology
How integrated strategy is reshaping biopharma growth
As biopharma organizations face growing complexity, integrated operating models are becoming a strategic advantage. In this interview, RevHealth CEO Ben…
Posted inBiotechnology
ASCO: Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
A first-in-class bispecific antibody-drug conjugate that Bristol Myers Squibb paid $800 million for has shown strong phase 3 results from…
Posted inGenetics
Multiomics Mass Spec Workflows in Drug Discovery
Credit: Jose A. Bernat Bacete / Getty Images Advances in end-to-end multiomics platforms and the underlying scientific knowledge now enable…
Posted inResearch
ASCO, Ryght AI team up for breast cancer trial site selection
The American Society of Clinical Oncology (ASCO) and Ryght AI are teaming up to identify research sites for an ASCO…
Posted inGenetics
Illuminating the Drug Development Path with Cell-Based Reporter Assays
Sponsored content brought to you by Selecting and advancing drug candidates through discovery and development is a long, resource-intensive process.…
Posted inGenetics
One Antibody, Fewer Scientific Surprises
Sponsored content brought to you by In biomedical research, promising programs rarely collapse for lack of scientific ambition. More often,…
Posted inGenetics
From Discovery to Development in Emerging Modalities
Sponsored content brought to you by The world of biologics is moving far beyond traditional monoclonal antibodies, and companies across…
Posted inBiotechnology
Rallybio swerves past Candid pothole to land deal with cancer drug developer Avenzo
Rallybio has steered its way to a new reverse merger, inking a deal with Avenzo Therapeutics weeks after a UCB buyout…
Posted inBiotechnology
Agios signs $165M deal for blood disorder drug from Korea’s Oscotec that flunked phase 2 study
Days after its lead clinical-stage drug suffered a setback, Agios Pharmaceuticals has rebounded by buying a blood disorder drug that…
Posted inBiotechnology
Lilly locks in 5-program R&D pact with China’s Haisco worth up to $3B, but targets unclear
Within hours of securing a gastrointestinal drug from Korea’s Hanmi Pharma, Eli Lilly has ramped up the biobucks for a…